# Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

> **NCT00635804** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 60 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** MK-3281
- **DRUG:** Placebo to MK-3281

## Key facts

- **NCT ID:** NCT00635804
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-19
- **Primary completion:** 2009-12-22
- **Final completion:** 2009-12-22
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635804, "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00635804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*